The article highlights the evolution of antibody-drug conjugates (ADCs) in the fight against breast cancer, from Paul Ehrlich's initial idea of a magic bullet to recent advancements that have transformed treatment, especially in patients with different levels of HER2. #CáncerDeMama #Anticuerpos #InvestigaciónOncológica (translated)












